Skip to main content
Year archive

Marinomed Biotech AG — 2025 filings

All 55 regulatory filings released by Marinomed Biotech AG (MARI) in 2025, sourced directly from the official regulator.

55 Filings
2025 Period
2025 filings (55)
Filing Released Lang
EQS-NVR: Marinomed Biotech AG: Release according to Article 135, Section 1 BörseG with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2025-10-31 English
EQS-NVR: Marinomed Biotech AG: Veröffentlichung der Gesamtstimmrechte nach § 135 Abs. 1 BörseG mit dem Ziel der europaweiten Verbreitung
Declaration of Voting Results & Voting Rights Announcements
2025-10-31 German
Release according to Article 135, Section 1 BorseG with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2025-10-31 English
EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Regulatory Filings
2025-10-06 English
EQS-Adhoc: Marinomed Biotech AG startet Prüfung strategischer Optionen für die Marinosolv- Plattform
M&A Activity
2025-10-06 German
Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Regulatory Filings
2025-10-06 English
Marinomed Biotech AG announces results for the first half year of 2025
Earnings Release H1 2025
2025-09-17 English
EQS-AFR: Marinomed Biotech AG: Release of a Financial report
Interim / Quarterly Report H1 2025
2025-09-17 English
EQS-AFR: Marinomed Biotech AG: Bekanntmachung über die Veröffentlichung eines Finanzberichtes
Interim / Quarterly Report H1 2025
2025-09-17 German
EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 61.607 no-par value bearer shares at an issue price of EUR 17,50 per share
Share Issue/Capital Change
2025-09-16 English
EQS-Adhoc: Marinomed Biotech AG beschließt Kapitalerhöhung unter Bezugsrechtsausschluss durch Ausgabe von 61.607 auf Inhaber lautenden Stückaktien zum Ausgabebetrag von EUR 17,50 je Aktie
Capital/Financing Update
2025-09-16 German
Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 61.607 no-par value bearer shares at an issue price of EUR 17,50 per share
Share Issue/Capital Change
2025-09-16 English
EQS-AGM: Marinomed Biotech AG: Convening of an Extraordinary General Meeting for Tuesday, 23 September 2025 at 1:00 p.m.
Proxy Solicitation & Information Statement
2025-09-02 English
EQS-HV: Marinomed Biotech AG: Einberufung einer außerordentlichen Hauptversammlung für Dienstag, den 23. September 2025 um 13:00 Uhr
Proxy Solicitation & Information Statement
2025-09-02 German
Marinomed Biotech AG: Convening of an Extraordinary General Meeting for Tuesday, 23 September 2025 at 1:00 p.m.
AGM Information
2025-09-02 English
EQS-Adhoc: Marinomed Biotech AG: Agreement on the key terms of the issue of a secured EUR 2.5mn convertible bond
Capital/Financing Update
2025-09-01 English
EQS-Adhoc: Marinomed Biotech AG: Einigung über die Eckpunkte der Emission einer besicherten EUR 2,5mio Wandelschuldverschreibung
Capital/Financing Update
2025-09-01 German
Marinomed Biotech AG: Agreement on the key terms of the issue of a secured EUR 2.5mn convertible bond
Capital/Financing Update
2025-09-01 English
Marinomed Biotech AG announces partnership for Budesolv in Switzerland
M&A Activity
2025-06-06 English
EQS-PVR: Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution
Major Shareholding Notification
2025-06-04 English
EQS-PVR: Marinomed Biotech AG: Veröffentlichung gemäß § 135 Abs. 2 BörseG mit dem Ziel der europaweiten Verbreitung
Declaration of Voting Results & Voting Rights Announcements
2025-06-04 German
Declaration of Voting Results & Voting Rights Announcements 2025
Declaration of Voting Results & Voting Rights Announcements
2025-06-04 English
EQS-PVR: Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2025-06-04 English
EQS-PVR: Marinomed Biotech AG: Veröffentlichung gemäß § 135 Abs. 2 BörseG mit dem Ziel der europaweiten Verbreitung
Declaration of Voting Results & Voting Rights Announcements
2025-06-04 German
EQS-AGM: Supplemented Version of the Convocation published on May 12, 2025 for the 8th Annual General Meeting for Wednesday, June 11, 2025 at 9:00 a.m. (Vienna time)
AGM Information
2025-05-14 English
EQS-HV: Ergänzte Fassung der am 12. Mai 2025 veröffentlichten Einberufung der 8. ordentlichen Hauptversammlung für Mittwoch, den 11. Juni 2025 um 9:00 Uhr (Wiener Zeit)
AGM Information
2025-05-14 German
Supplemented Version of the Convocation published on May 12, 2025 for the 8th Annual General Meeting for Wednesday, June 11, 2025 at 9:00 a.m. (Vienna time)
AGM Information
2025-05-14 English
EQS-AGM: Marinomed Biotech AG: Invitation to the 8th Annual General Meeting on Wednesday, June 11, 2025, at 09:00 (Vienna time)
AGM Information
2025-05-12 English
EQS-HV: Marinomed Biotech AG: Einberufung der 8. ordentlichen Hauptversammlung für Mittwoch, den 11. Juni 2025 um 09:00 Uhr (Wiener Zeit)
Proxy Solicitation & Information Statement
2025-05-12 German
Marinomed Biotech AG: Invitation to the 8th Annual General Meeting on Wednesday, June 11, 2025, at 09:00 (Vienna time)
AGM Information
2025-05-12 English
Marinomed Biotech AG announces results for the first quarter of 2025
Earnings Release Q1 2025
2025-05-08 English
EQS-AFR: Marinomed Biotech AG: Release of a Financial report
Audit Report / Information FY 2024
2025-04-16 English
EQS-AFR: Marinomed Biotech AG: Bekanntmachung über die Veröffentlichung eines Finanzberichtes
Annual Report (ESEF) FY 2024
2025-04-16 German
EQS-AFR: Marinomed Biotech AG: Bekanntmachung über die Veröffentlichung eines Finanzberichtes
Management Reports
2025-04-16 German
Report Publication Announcement 2025
Report Publication Announcement
2025-04-16 English
Marinomed Biotech AG: Launch of new moisturizing Carragelose eye drops in Austria
Regulatory Filings
2025-04-10 English
EQS-Adhoc: Marinomed Biotech AG wurde Opfer von Cyberkriminalität
Legal Proceedings Report
2025-04-02 German
Marinomed Biotech AG wurde Opfer von Cyberkriminalitat
Regulatory Filings
2025-04-02 German
Marinomed focuses on growth after successful restructuring
Earnings Release Q1 2025
2025-03-27 English
Marinomed Biotech AG: Successful completion of the sale of the Carragelose business to Unither Pharmaceuticals
M&A Activity
2025-03-01 English
Report Publication Announcement 2025
Report Publication Announcement
2025-02-28 English
EQS-AFR: Marinomed Biotech AG: Release of a Financial report
Interim / Quarterly Report H1 2024
2025-02-27 English
EQS-AFR: Marinomed Biotech AG: Bekanntmachung über die Veröffentlichung eines Finanzberichtes
Interim / Quarterly Report H1 2024
2025-02-27 German
Report Publication Announcement 2025
Report Publication Announcement
2025-02-27 English
Marinomed Biotech AG: Changes to the Management Board
Board/Management Information
2025-01-31 English
Marinomed Biotech AG: Simon Nebel, Erwerb: Erwerb der Aktien uber die engverbuendene Person Viopas Venture Consulting GmbH, aber auf eigene Rechnung.
Director's Dealing
2025-01-25 German
EQS-DD: Marinomed Biotech AG: Simon Nebel, Erwerb: Erwerb der Aktien über die engverbuendene Person Viopas Venture Consulting GmbH, aber auf eigene Rechnung.
Director's Dealing
2025-01-24 German
Marinomed Biotech AG: Simon Nebel, Erwerb: Erwerb der Aktien uber die engverbuendene Person Viopas Venture Consulting GmbH, aber auf eigene Rechnung.
Director's Dealing
2025-01-24 German
Marinomed Biotech AG: Dr. Karl Mahler, buy
Director's Dealing
2025-01-21 English
Marinomed Biotech AG: Restructuring proceedings successfully completed
Legal Proceedings Report
2025-01-21 English
EQS-DD: Marinomed Biotech AG: Dr. Karl Mahler, buy
Director's Dealing
2025-01-20 English
EQS-DD: Marinomed Biotech AG: Dr. Karl Mahler, Kauf
Director's Dealing
2025-01-20 German
Marinomed Biotech AG: Dr. Karl Mahler, buy
Director's Dealing
2025-01-20 English
Marinomed Biotech AG: Restructuring proceedings successfully completed
Legal Proceedings Report
2025-01-20 English
Release according to Article 135, Section 1 BorseG with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2025-01-01 English